153 related articles for article (PubMed ID: 25906044)
1. Quantitative structure-activity relationship study on BTK inhibitors by modified multivariate adaptive regression spline and CoMSIA methods.
Xu A; Zhang Y; Ran T; Liu H; Lu S; Xu J; Xiong X; Jiang Y; Lu T; Chen Y
SAR QSAR Environ Res; 2015; 26(4):279-300. PubMed ID: 25906044
[TBL] [Abstract][Full Text] [Related]
2. 2D Autocorrelation, CoMFA, and CoMSIA modeling of protein tyrosine kinases' inhibition by substituted pyrido[2,3-d]pyrimidine derivatives.
Caballero J; Fernández M; Saavedra M; González-Nilo FD
Bioorg Med Chem; 2008 Jan; 16(2):810-21. PubMed ID: 17964795
[TBL] [Abstract][Full Text] [Related]
3. Molecular Modeling Studies on Carbazole Carboxamide Based BTK Inhibitors Using Docking and Structure-Based 3D-QSAR.
Li R; Du Y; Gao Z; Shen J
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29671827
[TBL] [Abstract][Full Text] [Related]
4. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors.
Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF
J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710
[TBL] [Abstract][Full Text] [Related]
5. Receptor-guided 3D-QSAR studies, molecular dynamics simulation and free energy calculations of Btk kinase inhibitors.
Balasubramanian PK; Balupuri A; Kang HY; Cho SJ
BMC Syst Biol; 2017 Mar; 11(Suppl 2):6. PubMed ID: 28361711
[TBL] [Abstract][Full Text] [Related]
6. Molecular modeling studies on series of Btk inhibitors using docking, structure-based 3D-QSAR and molecular dynamics simulation: a combined approach.
Balasubramanian PK; Balupuri A; Cho SJ
Arch Pharm Res; 2016 Mar; 39(3):328-39. PubMed ID: 26699616
[TBL] [Abstract][Full Text] [Related]
7. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
8. Molecular modelling studies on cinnoline-based BTK inhibitors using docking and structure-based 3D-QSAR.
Li R; Du Y; Shen J
SAR QSAR Environ Res; 2018 Nov; 29(11):847-873. PubMed ID: 30280589
[TBL] [Abstract][Full Text] [Related]
9. Cholesteryl ester transfer protein inhibitors in coronary heart disease: Validated comparative QSAR modeling of N, N-disubstituted trifluoro-3-amino-2-propanols.
Mondal C; Halder AK; Adhikari N; Jha T
Comput Biol Med; 2013 Oct; 43(10):1545-55. PubMed ID: 24034746
[TBL] [Abstract][Full Text] [Related]
10. Molecular modelling studies for the discovery of new substituted pyridines derivatives with angiotensin II AT1 receptor antagonists.
Sharma MC
Interdiscip Sci; 2014 Sep; 6(3):197-207. PubMed ID: 25205497
[TBL] [Abstract][Full Text] [Related]
11. New Research for Quinazoline-2,4-diones as HPPD Inhibitors Based on 2D-MLR and 3D-QSAR Models.
Fu Y; Sun YN; Cao HF; Yi KH; Zhao LX; Li JZ; Ye F
Comb Chem High Throughput Screen; 2017; 20(9):748-759. PubMed ID: 28637410
[TBL] [Abstract][Full Text] [Related]
12. Exploring QSAR and pharmacophore mapping of structurally diverse selective matrix metalloproteinase-2 inhibitors.
Halder AK; Saha A; Jha T
J Pharm Pharmacol; 2013 Oct; 65(10):1541-54. PubMed ID: 24028622
[TBL] [Abstract][Full Text] [Related]
13. Combined 3D-QSAR, molecular docking, and molecular dynamics study on piperazinyl-glutamate-pyridines/pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.
Hao M; Li Y; Wang Y; Yan Y; Zhang S; Li G; Yang L
J Chem Inf Model; 2011 Oct; 51(10):2560-72. PubMed ID: 21923153
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR and molecular docking studies of 2-pyrimidinecarbonitrile derivatives as inhibitors against falcipain-3.
Potshangbam AM; Tanneeru K; Reddy BM; Guruprasad L
Bioorg Med Chem Lett; 2011 Dec; 21(23):7219-23. PubMed ID: 22018459
[TBL] [Abstract][Full Text] [Related]
15. 2D and 3D QSAR models for identifying diphenylpyridylethanamine based inhibitors against cholesteryl ester transfer protein.
Chen M; Yang X; Lai X; Gao Y
Bioorg Med Chem Lett; 2015 Oct; 25(20):4487-95. PubMed ID: 26346366
[TBL] [Abstract][Full Text] [Related]
16. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
Bavi R; Kumar R; Choi L; Woo Lee K
PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
[TBL] [Abstract][Full Text] [Related]
17. Structure-based quantitative structure-activity relationship studies of checkpoint kinase 1 inhibitors.
Du J; Xi L; Lei B; Lu J; Li J; Liu H; Yao X
J Comput Chem; 2010 Nov; 31(15):2783-93. PubMed ID: 20839304
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
Yi P; Fang X; Qiu M
Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
[TBL] [Abstract][Full Text] [Related]
20. 3D-QSAR studies of JNK1 inhibitors utilizing various alignment methods.
Madhavan T; Chung JY; Kothandan G; Gadhe CG; Cho SJ
Chem Biol Drug Des; 2012 Jan; 79(1):53-67. PubMed ID: 21722320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]